Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan

Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan GlobeNewswire October 01, 2024 Collaboration to include the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&TBuilds on long-standing relationship between the two companiesIn Japan around 90,000 new cases of prostate cancer are diagnosed each year PARIS, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has entered into a strategic partnership with PDRadiopharma Inc, a wholly-owned subsidiary of PeptiDream, for the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T.

Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan

Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan

Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan

Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan

Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan